436 related articles for article (PubMed ID: 19891972)
1. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
Deng Y; Theken KN; Lee CR
J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972
[TBL] [Abstract][Full Text] [Related]
2. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
[TBL] [Abstract][Full Text] [Related]
3. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
4. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
Nayeem MA; Geldenhuys WJ; Hanif A
Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
[TBL] [Abstract][Full Text] [Related]
5. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.
Schuck RN; Zha W; Edin ML; Gruzdev A; Vendrov KC; Miller TM; Xu Z; Lih FB; DeGraff LM; Tomer KB; Jones HM; Makowski L; Huang L; Poloyac SM; Zeldin DC; Lee CR
PLoS One; 2014; 9(10):e110162. PubMed ID: 25310404
[TBL] [Abstract][Full Text] [Related]
6. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
7. Arachidonic acid cytochrome P450 epoxygenase pathway.
Spector AA
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S52-6. PubMed ID: 18952572
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.
Theken KN; Schuck RN; Edin ML; Tran B; Ellis K; Bass A; Lih FB; Tomer KB; Poloyac SM; Wu MC; Hinderliter AL; Zeldin DC; Stouffer GA; Lee CR
Atherosclerosis; 2012 Jun; 222(2):530-6. PubMed ID: 22503544
[TBL] [Abstract][Full Text] [Related]
9. Roles of the epoxygenase CYP2J2 in the endothelium.
Askari A; Thomson SJ; Edin ML; Zeldin DC; Bishop-Bailey D
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():56-63. PubMed ID: 23474289
[TBL] [Abstract][Full Text] [Related]
10. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
11. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk.
Theken KN; Lee CR
Pharmacogenomics; 2007 Oct; 8(10):1369-83. PubMed ID: 17979511
[TBL] [Abstract][Full Text] [Related]
13. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.
Nayeem MA; Hanif A; Geldenhuys WJ; Agba S
Pharmacol Ther; 2022 Dec; 240():108213. PubMed ID: 35597366
[TBL] [Abstract][Full Text] [Related]
15. Inside epoxyeicosatrienoic acids and cardiovascular disease.
Tacconelli S; Patrignani P
Front Pharmacol; 2014; 5():239. PubMed ID: 25426071
[TBL] [Abstract][Full Text] [Related]
16. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
17. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
Zordoky BN; El-Kadi AO
Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
[TBL] [Abstract][Full Text] [Related]
18. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation.
Fleming I
Trends Pharmacol Sci; 2007 Sep; 28(9):448-52. PubMed ID: 17764757
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation.
Aliwarga T; Dinh JC; Heyward S; Prasad B; Gharib SA; Lemaitre RN; Sotoodehnia N; Totah RA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293289
[TBL] [Abstract][Full Text] [Related]
20. Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia.
Edin ML; Hamedani BG; Gruzdev A; Graves JP; Lih FB; Arbes SJ; Singh R; Orjuela Leon AC; Bradbury JA; DeGraff LM; Hoopes SL; Arand M; Zeldin DC
J Biol Chem; 2018 Mar; 293(9):3281-3292. PubMed ID: 29298899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
